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Summary
Background Although existing psoriasis treatments are effective and well tolerated
in many patients, there is still a need for new effective targeted treatment
options. Tofacitinib is an oral Janus kinase inhibitor that has been investigated in
patients with moderate-to-severe chronic plaque psoriasis.
Objectives To consider the benefits and risks of tofacitinib in patients with moder-
ate-to-severe psoriasis.
Methods Data were pooled from one phase II, four phase III and one long-term exten-
sion study comprising 5204 patient-years of tofacitinib treatment. Efficacy end points
included patients achieving Physician’s Global Assessments of ‘clear’ or ‘almost clear’,
≥ 75% and ≥ 90% reduction in Psoriasis Area and Severity Index (coprimary end
points) and improvements in Dermatology Life Quality Index score, Hospital Anxiety
and Depression Scale depression score and Itch Severity Item score, at weeks 16 and
52. Safety data were summarized for 3 years of tofacitinib exposure.
Results Tofacitinib 5 and 10 mg twice daily (BID) showed superiority over placebo
for all efficacy end points at week 16, with response maintained for 52 weeks of
continued treatment. Tofacitinib improved patients’ quality of life and was well tol-
erated. Rates of safety events of interest (except herpes zoster) were similar to those
in the published literature and healthcare databases for other systemic psoriasis
therapies. Tofacitinib 10 mg BID demonstrated greater efficacy than 5 mg BID.
Conclusions Tofacitinib has a benefit–risk profile in moderate-to-severe psoriasis
consistent with that of other systemic treatments.
What’s already known about this topic?
• Psoriasis is a chronic, systemic inflammatory disease, which has a significant impact
on patients’ health-related quality of life.
© 2018 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019) 180, pp67–75 67
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
• Although several existing psoriasis treatments are efficacious and well tolerated in
many patients, some patients require treatment switching, and a proportion of
patients remain untreated or undertreated.
• Potential challenges to the use of existing therapies include safety issues and lim-
ited efficacy in some patients with conventional oral psoriasis treatments, incon-
venience of topical treatments and the requirement for parenteral administration
of biologics.
What does this study add?
• Consistent efficacy and a safety profile consistent with that seen in rheumatoid
arthritis, psoriatic arthritis and ulcerative colitis were demonstrated for oral
tofacitinib in patients with moderate-to-severe psoriasis.
• Tofacitinib has a benefit–risk profile in patients with moderate-to-severe psoriasis
that is consistent with that of other systemic psoriasis treatments.
Psoriasis is a chronic, systemic inflammatory disease with a glo-
bal prevalence in the range of 1–3%.1–3 Several treatments are
available for psoriasis that are effective and well tolerated in
many patients.4,5 However, conventional systemic therapies are
associated with limited efficacy in some patients,4 clinical
response to biologics can decrease over time,6 and both types of
drugs have recognized safety issues.7,8 Consequently, some
patients with psoriasis switch between multiple treatments over
their lifetime, and a significant proportion of patients remain
untreated or undertreated.9
The treatment satisfaction of patients with psoriasis has
been reported to be poor, but it is generally higher with bio-
logical agents than with traditional therapies,9–11 due to the
better efficacy of biologics.10,11 However, patients generally
prefer oral to parenteral treatments.12
Tofacitinib is a Janus kinase inhibitor. In contrast to cur-
rent biological therapies, tofacitinib is administered orally.
This analysis aimed to assess the benefit–risk profile of
tofacitinib in patients with moderate-to-severe chronic
plaque psoriasis by pooling the data from six clinical
trials.13–18
Patients and methods
Study design
These analyses were based on pooled data from one phase II
double-blind randomized controlled trial (ClinicalTrials.gov
identifier NCT00678210),18 four phase III double-blind ran-
domized controlled trials (collectively referred to as the index
studies) (OPT Pivotal 1, NCT01276639;15 OPT Pivotal 2,
NCT01309737;15 OPT Compare, NCT01241591;14 OPT
Retreatment, NCT01186744)13 and one open-label long-term
extension study (NCT01163253).19 Further details of the study
designs and treatments are provided in Table S1 (see Supporting
Information).
Efficacy end points
The main efficacy end points for the current analyses were the
proportion of patients achieving Physician’s Global Assessment
(PGA) ratings of ‘clear’ or ‘almost clear’ and the proportion of
patients achieving ≥ 75% reduction in Psoriasis Area and
Severity Index (PASI 75) at weeks 16 and 52 of treatment
(these were the coprimary end points at week 16 in the OPT
Pivotal 1 and 2 studies). Other efficacy end points included
the proportions of patients achieving PASI 90; a score of ≤ 1
on the Dermatology Life Quality Index (DLQI), indicating no
effect of skin disease on the patient’s life;20 a score of ≤ 1 on
the Itch Severity Item (ISI), equating to ‘little or no itch’;21 a
depression score of < 8 on the Hospital Anxiety and Depres-
sion Scale (HADS), indicating no symptoms of depression;22
≥ 75% reduction in the Nail Psoriasis Severity Index (NAPSI
75) in patients with nail psoriasis at baseline; and change
from baseline in body surface area affected by psoriasis.
Safety end points
The incidence rates (IRs; numbers of patients with events per
100 patient-years) of serious infections, opportunistic infec-
tions, herpes zoster, major adverse cardiovascular events
(MACE), malignancy excluding nonmelanoma skin cancer
(NMSC), and NMSC were assessed. Treated infections that
required parenteral antimicrobial therapy, required hospitaliza-
tion or met other criteria that required the infection to be
reported as a serious adverse event (AE) were considered a
serious infection. Opportunistic infections, defined as infec-
tions that occur more frequently in immunocompromised
individuals, also included disseminated herpes zoster and her-
pes zoster affecting nonadjacent or more than two adjacent
dermatomes. MACE was defined as the occurrence of a
myocardial infarction, cerebrovascular event or cardiovascular
death. Independent adjudication committees, blinded to
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treatment assignment, reviewed all potential opportunistic
infections and all cardiovascular events.
Statistical analysis
Efficacy data
Data from OPT Pivotal 1 and OPT Pivotal 2, up to week 52,
were pooled for the efficacy analyses. The full analysis set
included all patients who were randomized and received at
least one dose of study drug in either Pivotal study.
For dichotomized data, missing observations were set to
nonresponders unless otherwise stated. The Cochran–Mantel–
Haenszel approach to adjust the study effect was used to esti-
mate the treatment difference among treatment groups at
week 16 (before placebo-treated patients advanced to
tofacitinib). Statistical testing was based on normal approxima-
tion to the binomial proportions. No statistical analyses were
applied to data beyond week 16.
Safety data
Data from patients who received at least one dose of
tofacitinib, including all events through to 4 April 2014
(interim data for the long-term extension study), were consid-
ered for the safety analyses.
Safety data from the phase II and III studies were summa-
rized for tofacitinib 5 mg and 10 mg twice daily (BID) over
16 weeks (vs. placebo) and over 1 year (no placebo arm; for
patients initially receiving placebo then advanced to tofacitinib
at week 16, the data after week 16 were included). Safety data
were also summarized for combined tofacitinib exposure for
up to 3 years in the index and long-term extension studies.
Total tofacitinib exposure data are presented for patients who
received tofacitinib 10 mg BID for ≥ 80% of their study dura-
tion (10-mg BID group) and for pooled tofacitinib doses
(tofacitinib all). For patients who switched from placebo or
etanercept to tofacitinib, a new baseline was established, with
the first day of tofacitinib treatment considered as day 1.
To contextualize IRs for safety events, a systematic review
of published randomized clinical trials and observational stud-
ies reporting AEs with other psoriasis treatments was under-
taken (Appendix S1 and Table S2; see Supporting
Information). Additionally, data from the six tofacitinib clini-
cal trials were benchmarked against two Pfizer-commissioned
comparison cohorts of patients with moderate-to-severe psori-
asis, derived from U.S. Medicare and Kaiser Permanente
Northern California (KPNC) databases (Appendix S1).
All clinical studies were conducted in compliance with the
ethical principles originating in or derived from the Declara-
tion of Helsinki and with the International Council for Har-
monisation Good Clinical Practice Guidelines. All
documentation was reviewed by the institutional review board
and/or independent ethics committee at each of the investiga-
tional centres. All patients provided written informed consent.
Results
Patients
For efficacy analyses, 745, 741 and 373 patients were
included who received tofacitinib 5 mg BID, tofacitinib
10 mg BID and placebo, respectively, in OPT Pivotal 1 and 2.
The patient demographics and baseline disease characteristics
have previously been reported for these patients and were bal-
anced between the treatment groups.15
For safety analyses during the 16-week placebo-controlled
period, the numbers of patients receiving at least one dose of
tofacitinib 5 mg BID, tofacitinib 10 mg BID and placebo were
1123 (299 patient-years of exposure), 1120 (302 patient-years)
and 530 (136 patient-years), respectively. For safety analyses
over 1 year, 1217 (801 patient-years) and 1219 (869 patient-
years) patients received at least one dose of tofacitinib 5 mg and
10 mg BID, respectively. For analyses of safety across all
tofacitinib-treated patients up to 3 years, 3623 patients were
included (5204 patient-years of exposure), and 2915, 2362,
995 and 55 patients had received treatment with tofacitinib for
at least 6 months, 1 year, 2 years and 3 years, respectively.
The demographic and other baseline characteristics for all
tofacitinib-treated patients are shown in Table S3 (see Sup-
porting Information). The median DLQI score was 11, indicat-
ing a very large effect of psoriasis on the patients’ quality of
life.23
Efficacy
Based on pooled data from the OPT Pivotal 1 and 2 studies,
significantly greater proportions of patients receiving
tofacitinib 5 mg or 10 mg BID vs. placebo achieved a PGA of
‘clear’ or ‘almost clear’ (440%, 591% and 100%, respec-
tively; P < 0001) and PASI 75 (431%, 594% and 89%,
respectively; P < 0001) at week 16 (Fig. 1a, b). Further
improvements were seen with both tofacitinib doses up to
week 28. At week 52, ≥ 57% of patients who achieved a PGA
response at week 16 and ≥ 66% of patients who achieved PASI
75 at week 16 maintained that response.
The more stringent efficacy thresholds of PASI 90 and
NAPSI 75 were also achieved in more patients receiving tofaci-
tinib 5 mg or 10 mg BID than placebo at week 16 (PASI 90:
222%, 391% and 30%, respectively; P < 0001; NAPSI 75:
169%, 281% and 68%, respectively; P < 0001) (Fig. 1c,
d). At week 52, ≥ 65% of those who achieved PASI 90 at
week 16 maintained that response.
At week 16, a DLQI total score ≤ 1 and an ISI score ≤ 1
were achieved in significantly more patients receiving
tofacitinib 5 mg or 10 mg BID (DLQI: 277% and 443%,
respectively; ISI: 430% and 609%, respectively) than placebo
(DLQI: 53%; ISI: 105%; P < 0001) (Fig. 1e, f). The propor-
tions of patients achieving a DLQI total score ≤ 1, and an ISI
score ≤ 1 continued to increase to week 28. Of those patients
who had a HADS depression score indicative of depression
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(≥ 8) at baseline, a higher proportion receiving tofacitinib 5
mg BID (524%) or 10 mg BID (616%) compared with pla-
cebo (358%) had a HADS depression score indicating they
were not depressed (< 8) at week 16 (Fig. S1; see Supporting
Information).
Tofacitinib was efficacious in subgroups of patients with
moderate or severe disease, who had previous experience of
systemic treatment or were systemic treatment naive, and who
had lower or higher bodyweight. Tofacitinib 10 mg BID
showed greater efficacy than 5 mg BID in all subgroups, and
the overall efficacy was lower in patients with baseline PASI
< 20, prior experience of systemic treatment and bodyweight
≥ 90 kg at baseline (Table 1).
Safety
Safety data from patients with psoriasis receiving 16 weeks of
treatment with tofacitinib 5 mg and 10 mg BID vs. placebo
Fig 1. Proportions of patients (mean  SE) achieving (a) Physician’s Global Assessment (PGA) response of ‘clear’ or ‘almost clear’, (b) ≥ 75%
improvement in Psoriasis Area and Severity Index (PASI 75), (c) PASI 90, (d) ≥ 75% improvement in Nail Psoriasis Severity Index (NAPSI 75),
(e) Dermatology Life Quality Index (DLQI) response and (f) Itch Severity Item (ISI) response (full analysis set, nonresponder imputation). aOf
those patients with nail psoriasis at baseline, bof those patients with baseline DLQI > 1, cof those patients with baseline ISI > 1. **P < 00001
tofacitinib vs. placebo; ††P < 00001 tofacitinib 10 mg twice daily (BID) vs. tofacitinib 5 mg BID. P-values are shown at week 16 only (the time
at which the main efficacy end points were collected across the various studies).
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have been previously reported.15 During the placebo-con-
trolled period, AEs were reported in 606 (540%) patients
who received tofacitinib 5 mg BID, 660 (589%) who
received tofacitinib 10 mg BID and 267 (504%) who
received placebo; 29 (26%), 35 (31%) and 26 (49%),
respectively, discontinued treatment due to AEs.
During 1 year of treatment with tofacitinib 5 mg and
10 mg BID, there were few dose-related differences in the IRs
for events of special interest. Although IRs for serious infec-
tions, herpes zoster and NMSC were numerically greater with
tofacitinib 10 mg BID than with 5 mg BID, the 95%
confidence intervals (CIs) overlapped (Table S4; see Support-
ing Information).
Across all tofacitinib-treated patients in the six clinical trials
included in this analysis, the most frequently observed serious
infections were pneumonia (n = 16, 04%), herpes zoster
(n = 8, 02%) and appendicitis (n = 7, 02%). There was no
association between the occurrence of serious infections and
cases of confirmed neutropenia or lymphopenia. Opportunistic
infections were infrequent, with 12 infections adjudicated to
be opportunistic, and no dose dependency was observed. Nine
herpes zoster events, reported in eight of the 130 patients
with herpes zoster (6%), were adjudicated to be opportunistic
infections. Other opportunistic infections were listeria
encephalitis, fungal pneumonia, herpes simplex meningitis
and cryptococcal pneumonia, each reported in one patient,
and all of which resolved on anti-infective treatment.
Of the 130 cases of herpes zoster, > 90% were classified as
mild or moderate in severity. Most cases of herpes zoster
resolved with antiviral therapy without complication; eight
patients discontinued due to herpes zoster. Postherpetic neu-
ralgia (PHN) was reported by 10 (8%) of the tofacitinib-trea-
ted patients with herpes zoster, equating to 03% of all the
tofacitinib-treated patients and an IR of 019 per 100 patient-
years. A higher IR for herpes zoster was observed in Asian
(particularly Japanese) patients with psoriasis receiving
tofacitinib: the IR (95% CI) over the total tofacitinib exposure
for Asian patients was 575 (365–863), compared with 255
(213–303) for the global population.
The IR of malignancies excluding NMSC was similar between
patients receiving tofacitinib 5 mg and 10 mg BID. The IRs
(95% CIs) for total exposure were 097 (064–140) and 100
(075–131) for tofacitinib 10 mg BID and all tofacitinib doses,
respectively. No increase in the IR of malignancies excluding
NMSC was observed over time in patients treated with
tofacitinib for up to 3 years. The IR of NMSC was higher in
patients receiving tofacitinib 10 mg BID over 1 year compared
with 5 mg BID (Table S4). The IRs (95% CIs) for total exposure
were 090 (058–133) and 074 (052–101) for tofacitinib 10
mg BID and all tofacitinib doses, respectively. Of the adjudicated
cardiovascular events, 19 occurring in patients receiving tofaci-
tinib were considered to be MACE during the entire tofacitinib
exposure, with no dose dependency observed over 1 year
(Table S4). The IRs (95% CIs) for MACE over the total tofaci-
tinib exposure were 032 (015–061) and 037 (022–057)
for tofacitinib 10 mg BID and all tofacitinib doses, respectively.
During the placebo-controlled phases of the psoriasis clinical
trials analysed in this study, the IR of death for patients receiving
tofacitinib was low and comparable with that observed in the
placebo treatment groups. Across all studies, there was a total of
10 deaths up to 30 days after discontinuation of tofacitinib,
with an IR of 019 (95% CI 009–035). By comparison, there
was one death in a patient receiving placebo (IR 073, 95% CI
002–409) and no deaths reported in patients receiving etaner-
cept. Of note, only 335 patients received etanercept for up to
12 weeks (747 patient-years of exposure) and only 530
patients received placebo for 12–16 weeks (136 patient-years of
exposure). Causes of death in patients receiving tofacitinib
included myocardial infarction (n = 4), cardiac arrest (n = 2),
acute respiratory distress syndrome (n = 1), lung cancer (n = 1),
hepatic failure (n = 1) and road traffic accident (n = 1).
Changes were seen in some laboratory parameters in
patients receiving tofacitinib.13–15 Small, dose-dependent
decreases in haemoglobin, stable after 3 months of treatment
and reversible on treatment withdrawal, were observed. Across
all tofacitinib-treated patients in the six studies, the mean 
SE change from baseline to the last observation in haemoglo-
bin levels was 034  002 g dL1. Small mean decreases in
Table 1 Proportions of patients achieving ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) with tofacitinib 10 mg twice daily
(BID) vs. tofacitinib 5 mg BID by subgroup (full analysis set, nonresponder imputation)
Week 16 Week 52
Tofacitinib 5 mg
BID (n = 739)
Tofacitinib 10 mg
BID (n = 734)
Tofacitinib 5 mg
BID (n = 739)
Tofacitinib 10 mg
BID (n = 734)
Baseline PASI
< 20 386 (337–436) 571 (520–622) 365 (316–414) 497 (446–549)
≥ 20 475 (425–526) 617 (568–667) 444 (393–494) 541 (500–592)
Previous systemic treatment
No 570 (506–633) 700 (645–756) 542 (479–606) 642 (584–701)
Yes 364 (322–406) 536 (491–581) 340 (299–381) 452 (407–496)
Baseline weight
< 90 kg 460 (413–508) 627 (580–673) 450 (402–497) 564 (517–612)
≥ 90 kg 391 (337–445) 551 (496–606) 343 (290–396) 459 (404–514)
Values are the percentage (95% confidence interval).
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neutrophil counts were observed at week 4, gradually revert-
ing back towards baseline values after week 8, and generally
stabilizing after month 4. Increases in lymphocyte counts were
seen at week 4, persisting through week 8, followed by slight
decreases through month 24. Across all tofacitinib-treated
patients, the mean change from baseline to the last observa-
tion in neutrophil count was 004 9 109 cells L1, and in
lymphocyte count it was 018 9 109 cells L1.
Small, nonprogressive increases occurred in mean total
cholesterol, high-density lipoprotein (HDL) cholesterol, low-
density lipoprotein (LDL) cholesterol and triglycerides, but
total : HDL cholesterol or LDL : HDL cholesterol ratios were
unaffected. Across all tofacitinib-treated patients, the mean 
SE percentage changes from baseline to the last observation
were 99  035% for total cholesterol, 120  057% for
LDL cholesterol, 125  040% for HDL cholesterol and 146
 113% for triglycerides. Small, dose-dependent median (in-
terquartile range) increases in aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) levels were
observed over 1 year of treatment: 25 IU L1 (10 to 70)
for AST and 20 IU L1 (20 to 90) for ALT in the tofaci-
tinib 5 mg BID group, and 30 IU L1 (10 to 90) for AST
and 30 IU L1 (30 to 110) for ALT in the tofacitinib 10
mg BID group; they did not increase further on longer expo-
sure. There were no confirmed cases of Hy’s law or drug-
induced liver injury.
IRs of safety events reported in published randomized con-
trolled trials and observational studies, and those reported in
the Pfizer-commissioned comparison cohorts (Medicare and
KPNC) for other systemic psoriasis treatments, are summarized
in Table 2, alongside data from the tofacitinib clinical pro-
gramme. Detailed results are given in Figure S2 (see Support-
ing Information).
Discussion
Despite a range of biological treatment options being available
for plaque psoriasis, orally administered agents with clinically
meaningful efficacy and an acceptable safety profile with long-
term use are needed. The efficacy of tofacitinib in patients
with moderate-to-severe psoriasis has been demonstrated in
the extensive clinical development programme, with improve-
ments observed for all clinical end points and quality of life.
Together with safety data from 5204 patient-years of exposure
to tofacitinib, these findings suggest a benefit–risk profile for
tofacitinib in psoriasis that is consistent with those of other
systemic treatments.
Significant differences for tofacitinib vs. placebo were seen
for all efficacy end points at week 16. A loss of efficacy was
seen in some patients after 28 weeks; the mechanism of action
for this is unknown, and a clinical response is maintained in
many patients for up to 2 years.19 Improvements in nail psori-
asis (reported to be nonresponsive to traditional psoriasis
treatments),24,25 relief of itch within 2 days of treatment,14
sustained improvements in quality of life, and improvements
in the HADS depression score were seen with both tofacitinib
doses. Tofacitinib 5 mg BID has consistently demonstrated
superior efficacy to placebo, and tofacitinib 10 mg BID has
shown additional efficacy compared with 5 mg BID.13–15
Based on the results of OPT Compare (NCT01241591),
tofacitinib 10 mg BID had similar efficacy to etanercept
50 mg twice weekly (PASI 75: 636% and 585%, respec-
tively; PGA response: 682% and 663%, respectively),
whereas 5 mg BID did not meet the noninferiority criteria
(PASI 75: 395%; PGA response: 471%).14 A meta-analysis
conducted by Pfizer has shown the efficacy of tofacitinib 5 mg
BID to be similar to those of oral methotrexate and etanercept
25 mg twice weekly, and numerically higher than with the
oral psoriasis therapies acitretin and apremilast.26 The meta-
analysis also showed the efficacy of tofacitinib 10 mg BID to
be in the range of those of injectable tumour necrosis factor
antagonists (currently the most widely prescribed biological
drugs for psoriasis), similar to that of ciclosporin, and greater
than those of other oral treatments (apremilast, acitretin, oral
methotrexate and fumarates).26,27
Tofacitinib demonstrated efficacy in subgroups defined by
baseline PASI score, prior systemic treatment and bodyweight.
Lower efficacy was seen in patients with PASI baseline score
Table 2 Incidence rate ranges (events per 100 patient-years) for safety events of interest reported in randomized controlled trials, observational
studies, Pfizer-commissioned comparison cohorts (Medicare, KPNC) and the tofacitinib clinical trials
Published
RCTsa
Published
observational studies
Medicare comparison
cohort
KPNC comparison
cohort
Tofacitinib
allb
Serious infections 0–455 083–262 NA 151–217 168
Herpes zoster 475 000–323 111–143 086–103 255
Malignancies (excluding NMSC) 0–769 054–29 050–129 075–115 100
NMSC 0–208 007–189 224–536 114–124 074
MACE 0–116 036–445c NA NA 037
KPNC, Kaiser Permanente Northern California; MACE, major adverse cardiovascular events; NA, not available; NMSC, nonmelanoma skin can-
cer. aPublished randomized controlled trial (RCT) data refer to data from the full duration (typically 1 year) of clinical trials of agents other
than tofacitinib (secukinumab, ustekinumab, adalimumab, etanercept, infliximab, apremilast and oral methotrexate); they do not include data
from long-term extension phases. bIncludes data for combined tofacitinib exposure for up to 3 years in the index and long-term extension
studies. cRange cited is for rates where definition of MACE included any death. When cardiovascular death only was included, the upper
bound was 222 rather than 445 events per 100 patient-years.
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< 20, higher bodyweight and prior systemic treatment, as has
been observed with biological therapy.28,29
Tofacitinib 5 mg BID and 10 mg BID were generally well
tolerated, and safety events were similar to those reported
with tofacitinib in rheumatoid arthritis, ulcerative colitis and
psoriatic arthritis.30–34 Only one study is available comparing
tofacitinib head to head with another psoriasis treatment,14
and comparisons between treatments must therefore be inter-
preted cautiously. However, comparisons with data from pub-
lished studies and Pfizer-commissioned comparison cohorts
demonstrate that, with the exception of herpes zoster, rates of
key safety events in the tofacitinib clinical trials analysed fall
within the range of rates for the same events across a range of
systemic psoriasis therapies. IRs for herpes zoster were gener-
ally higher in the tofacitinib clinical trials in the comparison
cohorts, although there was some overlap in the CIs around
estimates for tofacitinib and ustekinumab in the Medicare
comparison cohort (Fig. S2d; see Supporting Information).
The rates were also higher than the majority of those in
published observational studies, but were lower than the esti-
mate for ustekinumab in one publication, and the 95% CIs
overlapped those around estimates for ciclosporin, infliximab,
oral methotrexate with biologics, acitretin with biologics and
psoralen plus ultraviolet A (Fig. S2c; see Supporting Informa-
tion). The majority of cases of herpes zoster were nonserious,
were of mild or moderate severity and resolved on treatment.
PHN was reported by 8% of patients receiving tofacitinib who
experienced herpes zoster (IR for PHN: 02 per 100 patient-
years); no published data on the rates of PHN in patients with
psoriasis were found in the literature.
IRs of serious infections and herpes zoster were numerically
higher with tofacitinib 10 mg BID than with 5 mg BID; how-
ever, the IR of serious infections with tofacitinib 10 mg BID
was below that reported in some observational studies for
tumour necrosis factor antagonists (Table S2), and the dose-
dependent difference in the IR for herpes zoster was fairly
small (13%). Given the greater observed efficacy of the
higher dose of tofacitinib, the overall benefit–risk profile of
tofacitinib 10 mg BID is maintained and consistent with those
of other systemic treatments for moderate-to-severe psoriasis.
In the global clinical studies in psoriasis, patients in Japan
were noted to show an increased incidence of herpes zoster
compared with other patients, reflecting findings reported
elsewhere.35
A number of changes in laboratory parameters were seen in
patients receiving tofacitinib in the psoriasis clinical trials
analysed in this study, but they were reversible upon with-
drawal of tofacitinib. There were no indications that tofaci-
tinib was associated with the safety issues that are seen with
oral methotrexate treatment, such as hepatic toxicity36–38 or
bone marrow suppression,37,39 or with the renal toxicity
known to be associated with ciclosporin use;39 these findings
are supported by data from 4967 patients with rheumatoid
arthritis and a total tofacitinib exposure of 17 738 patient-
years that also showed no indication of hepatic or renal toxic-
ity with tofacitinib.31
The authors acknowledge some limitations of this study.
The study included data from clinical trials, and the selection
criteria for the trials were such that the study populations may
not fully reflect the characteristics of patients seen in everyday
clinical practice. The clinical trials included limited numbers
of patients and involved relatively short follow-up periods
compared with the time course of a chronic disease like psori-
asis, and therefore estimates of rare safety events, such as
malignancies, may be less reliable than when long-term data
are available.
As psoriasis is a chronic disease, often occurring from an
early age, over their lifetimes most patients will receive multi-
ple therapies, with some not responding well to any; there is
therefore an unmet need for new and effective treatment
options with acceptable safety profiles. While the efficacy of
tofacitinib is somewhat lower than that of some biological
psoriasis treatments, the efficacy of tofacitinib 10 mg BID is
comparable with that of etanercept 50 mg twice weekly.26
The safety profile of tofacitinib is generally comparable with
that of biologics, with the exception of the higher rates of her-
pes zoster seen with tofacitinib. However, the parenteral admin-
istration of biologics might be an issue for some patients. The
oral route of administration of tofacitinib is more convenient
and may be preferred by patients over subcutaneous injection or
intravenous infusion;12,40,41 it also bypasses the risk of injec-
tion- or infusion-site-related AEs, one of the most frequently
reported AEs for biological therapies.42,43
Overall, tofacitinib has a benefit–risk profile in patients with
moderate-to-severe plaque psoriasis consistent with those of
other systemic psoriasis treatments, with significant improve-
ment in clinical signs and symptoms and an acceptable safety
profile.
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